The next breakthrough in pharma may not come from a better molecule alone. It may come from better coordination.
The next breakthrough in pharma may not come from a better molecule alone. It may come from better coordination. Drug development is an incredibly complex process. Scientific research, manufacturing, clinical trials, regulatory work, data analysis, and external partners all have to move together. And when one part changes, the consequences can ripple across the entire program. That's where the latest advances in AI are becoming particularly interesting. AI is moving beyond simply helping researchers analyze biological and chemical questions. It's increasingly being designed to connect scientific insights with the operational workflows that turn those insights into medicines. A recent example is Orchestra Bio, whose technology is designed to help biopharma teams track studies, identify downstream impacts when something changes, and surface potential next steps. And now, OpenAI has acquired Orchestra Bio, bringing its team and technology into its life-sciences platform, Rosalin...